Patient-Derived Mouse Models of Cancer

R.M. Hoffman has been a cancer researcher since 1965.  Dr. Hoffman is the pioneer of the patient-derived orthotopic xenograft (PDOX) mouse model, which is featured in the present volume.  Dr. Hoffman is a pioneer in many areas of cancer research described in his almost 1,000 scientific publications that have been cited more than 35,000 times with an h-index of almost 100.  Dr. Hoffman is currently a Professor of Surgery at the University of California San Diego and Founding President of AntiCancer Inc.

• In memorium:  Jorgen Rygaard (1934-2016) Father of patient derived mouse models of cancer and modern cancer research.- The revival of patient-derived mouse models of cancer:  way back to the future.- Patient-derived xenograft models for human cancer, The Freiburg experience.- From Ectopic to Orthotopic Tumor Grafting Sites: Evidence for a Critical Role of the Host Tissue Microenvironment for the Actual Expression of the Malignant Phenotype.- The Effects of the Organ Microenvironment on Metastatic-Cell Gene Signatures.- Techniques for surgical orthotopic implantation of human tumors to immunodeficient mice.- The first patient-derived orthotopic xenograft (PDOX) mouse models of cancer: Cancer of the colon, pancreas, lung, breast, ovary, and mesothelioma.- Patient-derived xenograft models of prostate cancer.- Patient-Derived Mouse Models of Sarcoma.-  Cervical cancer patient-derived orthotopic xenograft (PDOX) models.- The use of pediatric patient-derived xenografts foridentifying novel agents and combinations.- Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics.- Use of patient-derived orthotopic xenografts (PDOX) to evaluate transformative cancer therapeutics.- Fluorescent protein-expressing transgenic nude mice as hosts for patient tumors.- Fluorescence imaging of tumors in human patient-derived orthotopic xenograft (PDOX) mouse models:  The iPDOX model.- The use of patient-derived orthotopic xenograft (PDOX) models to develop curative fluorescence-guided surgery of cancer.-Molecular characteristics of patient-derived tumor xenografts: genomic similarity to patient tumors and relevance for biomarker discovery.- Complementarity of patient-derived orthotopic xenografts (PDOX) models and molecular profiling for optimal therapy.- 3D Cell Culture Models.- Why patient derived mouse models need to be orthotopic.- Foreward: The future of patient-derived models of cancer.